A phase 3, multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study of 5% sofpironium bromide (BBI‐4000) gel in Japanese patients with primary axillary hyperhidrosis

A phase 3 study was conducted to verify the efficacy and safety of 5% sofpironium bromide (BBI‐4000) gel (hereinafter referred to as sofpironium) administrated for 6 weeks in Japanese patients with primary axillary hyperhidrosis. The primary efficacy end‐point was the proportion of patients who sati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokozeki, Hiroo, Fujimoto, Tomoko, Abe, Yoichiro, Igarashi, Masaru, Ishikoh, Akiko, Omi, Tokuya, Kanda, Hiroki, Kitahara, Hiroto, Kinoshita, Miwako, Nakasu, Ichiro, Hattori, Naoko, Horiuchi, Yuki, Maruyama, Ryuji, Mizutani, Haruko, Murakami, Yoshiyuki, Watanabe, Chiharu, Kume, Akihiro, Hanafusa, Takaaki, Hamaguchi, Masamitsu, Yoshioka, Akira, Egami, Yuriko, Matsuo, Keizo, Matsuda, Tomoko, Akamatsu, Motoki, Yorozuya, Toshiyuki, Takayama, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986147/
https://www.ncbi.nlm.nih.gov/pubmed/33410265
http://dx.doi.org/10.1111/1346-8138.15668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986147/
https://www.ncbi.nlm.nih.gov/pubmed/33410265
http://dx.doi.org/10.1111/1346-8138.15668

Ejemplares similares